We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GeneGo Rolls out MetaMiner Cystic Fibrosis
News

GeneGo Rolls out MetaMiner Cystic Fibrosis

GeneGo Rolls out MetaMiner Cystic Fibrosis
News

GeneGo Rolls out MetaMiner Cystic Fibrosis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GeneGo Rolls out MetaMiner Cystic Fibrosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GeneGo, Inc. has announced the release of MetaMiner Cystic Fibrosis, a first of its kind software and database platform designed to help advance drug discovery for cystic fibrosis, a life-threatening genetic disease. This disease-specific tool will provide the cystic fibrosis research community with methods for integrating and analyzing cystic fibrosis data.

Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the Cystic Fibrosis Foundation, provided funding and guidance to the project with the goal of leveraging systems biology technology and accumulating data in order to accelerate drug discovery for this disease. Cystic fibrosis affects 30,000 people in the United States, and ten million Americans are symptomless carriers of a CF gene.

"MetaMiner Cystic Fibrosis is an important new tool for the cystic fibrosis research community," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "It will allow the integration of important new results with existing literature and speed up the rate of insights that can lead to new therapeutic interventions."

"We are very pleased to announce the completion of the initial phase of the project," said Julie Bryant, GeneGo's VP of Business Development.

"We enjoyed working with the Foundation and the team of world-class experts they assembled for this project. In phase one, we built a database of all relevant small experiments information on the disease as well as over 30 cystic fibrosis specific pathway maps and networks. We believe this environment will help find a cure for cystic fibrosis faster as we move in to the next phase of the collaboration,” Bryant continued.

MetaMiner Cystic Fibrosis includes off-the-shelf GeneGo products -- MetaCore, MetaDrug and MapEditor -- as well as cystic fibrosis experiments content annotated by GeneGo in the form of disease maps, networks and a database of biomarkers and active compounds.

A committee of researchers from the cystic fibrosis community guided the cystic fibrosis-specific annotation under the sponsorship of CFFT. MetaMiner Cystic Fibrosis provides researchers with the ability to interpret emerging data from global experiments, like arrays or proteomics, and link it with published literature on cystic fibrosis.

Advertisement